Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer.
Ratings
3 / 5
3 ratings in the last 12 months
5
4
3
2
1
CEO
Mr. Daniel O’Day$95.3B
Market Cap • 25/07/20241987
(há 37 anos)
1992
(32 years ago)
NASDAQ
ListagemS&P500 Participant
Index Composite • 2024
Foster
Sede • California17.000
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
GILDSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.